News | March 24, 2010

Mayo Clinic Finds Cardiac Rehabilitation Helps Stent Patient Survival

March 24, 2010 – A team of Mayo Clinic researchers found that cardiac rehabilitation is associated with significantly reduced mortality rates for patients who receive coronary stents. The findings were presented last week at the annual meeting of the American College of Cardiology in Atlanta.

Researchers found patients who had coronary angioplasty and afterwards participated in a cardiac rehabilitation program had a 45 to 47 percent decrease in mortality compared to those who did not participate in a cardiac rehabilitation program.

“Patients need to know that once they’ve had a coronary artery stent placed, they are not cured,” says Randal Thomas, M.D., a preventive cardiologist at Mayo Clinic in Rochester, Minn. “Participation in a cardiac rehabilitation program will improve their health outcomes and quality of life.”

The study is one of very few that has looked at mortality rates after coronary angioplasty. “No other studies have been able to include the clinical details we have included,” says Dr. Thomas. The research team examined the records from a special database of 2,351 Mayo Clinic patients who underwent coronary angioplasty between 1994 and 2008. The overall participation rate in cardiac rehabilitation was 40 percent. Individual patients were followed for an average of six years.

In cardiac rehabilitation programs, patients exercise rigorously and get help in controlling risk factors. This leads to health benefits that are evident within the first year, and grow even larger over the long term, Dr. Thomas says.

Although cardiac rehabilitation programs are beneficial, Dr. Thomas says only 20 percent of all eligible cardiac patients nationally and 60 percent of Mayo patients participate. Several factors produce barriers to participation.

“Cardiac rehabilitation wasn’t covered by insurance for patients undergoing angioplasty therapy until 2006,” Dr. Thomas says. “Many patients and providers don’t know that it’s covered now. Also, some patients live far away from a cardiac rehabilitation facility. But what’s most troubling is that physicians often fail to emphasize the need for cardiac rehabilitation with their patients.”

“Cardiac rehabilitation is like a life raft to carry them [heart procedure patients] through the turbulent white water of cardiac trouble,” Dr. Thomas says. “It’s very important that they participate in such a program.”

The study was funded by the Mayo Clinic Division of Cardiology. Co-authors include Kashish Goel, MBBS; Ryan Lennon; R. Thomas Tilbury, M.D.; and Ray Squires, Ph.D., all of Mayo Clinic.

For more information: www.mayo.edu

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init